3 reasons why Indian pharma is getting ready for unstoppable growth

September 7, 2024

For Indian pharmaceutical companies, this scenario presents a distinct opportunity. Leveraging their established expertise and leadership in global COVID-19 vaccine distribution, along with robust supply chain efficiencies, Indian firms are strategically positioned to capitalize on this market shift. The departure of Chinese players from the market opens a significant gap, which Indian companies are well-equipped to fill .

More To Explore

Mahi Madhusudan Kela, Authum Investment offer to buy Prataap Snacks 26% stake at Rs 865.66 per share

Prataap Snacks has received an open offer from Authum Investment & Infrastructure and Mahi Madhusudan Kela to acquire 26.01% equity at ₹865.66 per share, totaling

January 8, 2025

Former Chief Investment Officer, his sister settle front-running case by paying Rs 91 lakh. Details here

A former CIO and his sister settled a Sebi front-running case by paying ₹91 lakh and accepting a six-month market ban. Sebi’s probe uncovered ₹27.77

January 8, 2025

Advertiser Disclosure

Great-investor.com helps users across the globe to find out The latest news, Guides, and Info about finance and investments. Furthermore, our content and research teams do not participate in any advertising planning nor are they permitted access to advertising campaign data.

Disclaimer

It is our organization’s primary mission to provide reviews, commentary, and analysis that are unbiased and objective. While great-investor.com has some data verified by industry participants, it can vary from time to time. Operating as an online business, this site may be compensated through third party advertisers. Our receipt of such compensation shall not be construed as an endorsement or recommendation by great-investor.com, nor shall it bias our reviews, analysis, and opinions. Please see our General Disclaimers for more information

Top10 International FZ LLE | 17th Floor, Creative Tower | 4422 | Fujairah | TRN: 100608946800003